<SEC-DOCUMENT>0001171843-17-005578.txt : 20170918
<SEC-HEADER>0001171843-17-005578.hdr.sgml : 20170918
<ACCEPTANCE-DATETIME>20170918073014
ACCESSION NUMBER:		0001171843-17-005578
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20170918
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170918
DATE AS OF CHANGE:		20170918

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PAIN THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001069530
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911911336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29959
		FILM NUMBER:		171088996

	BUSINESS ADDRESS:	
		STREET 1:		7801 N CAPITAL OF TEXAS HIGHWAY
		STREET 2:		SUITE 260
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78731
		BUSINESS PHONE:		512-501-2444

	MAIL ADDRESS:	
		STREET 1:		7801 N CAPITAL OF TEXAS HIGHWAY
		STREET 2:		SUITE 260
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78731
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k_091517.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html><head><title></title></head><body><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;"><font style="font-size: 10pt;">&#160;</font></div></div><p style="text-align: center;"><font style="font-size: 14pt;"><strong>UNITED STATES</strong><br><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br><strong>Washington, D.C. 20549</strong><br>_____________________</font></p><p style="text-transform: uppercase; text-align: center;"><font style="font-size: 14pt;"><strong>Form 8-K</strong><br>_____________________</font></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>CURRENT REPORT</strong></font></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</strong></font></p><p align="center"><font style="font-size: 10pt;">Date of Report (Date of earliest event Reported): <!--September 18, 2017-->September 18, 2017 &#160;</font></p><p align="center"><font style="font-size: 12pt;"><strong>Pain Therapeutics, Inc.</strong></font><br><font style="font-size: 10pt;">(Exact Name of Registrant as Specified in Charter)</font></p><table style="width: 100%;" border="0" cellspacing="0" cellpadding="0"><tr valign="top"><td align="center" width="33%"><font style="font-size: 10pt;"><strong>Delaware </strong></font></td><td align="center" width="34%"><font style="font-size: 10pt;"><strong>000-29959</strong></font></td><td align="center" width="33%"><font style="font-size: 10pt;"><strong>91-1911336</strong></font></td></tr><tr valign="top"><td align="center" width="33%"><font style="font-size: 10pt;">(State or Other Jurisdiction of Incorporation)</font></td><td align="center" width="34%"><font style="font-size: 10pt;">(Commission File Number)</font></td><td align="center" width="33%"><font style="font-size: 10pt;">(I.R.S. Employer Identification Number)</font></td></tr></table><p><font style="font-size: 10pt;">&#160;</font></p><table style="width: 100%;" border="0" cellspacing="0" cellpadding="0"><tr valign="bottom"><td align="center" width="50%"><font style="font-size: 10pt;"><strong>7801 N Capital of Texas Highway, Suite 260, Austin, TX 78731</strong><!----></font></td></tr><tr valign="top"><td align="center" width="50%"><font style="font-size: 10pt;">(Address of Principal Executive Offices) (Zip Code)</font></td></tr></table><p align="center"><font style="font-size: 10pt;"><strong>512-501-2444</strong><br>(Registrant's telephone number, including area code)</font></p><p align="center"><font style="font-size: 10pt;"><strong>Not Applicable</strong><br>(Former name or former address, if changed since last report)</font></p><table style="width: 100%;" border="0" cellspacing="0" cellpadding="0"><tr valign="top"><td colspan="3"><font style="font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:<br><br></font></td></tr><tr valign="top"><td width="21"><font style="font-size: 10pt;">&#160;</font></td><td width="40"><font style="font-size: 10pt;">[  ]</font></td><td nowrap="nowrap"><font style="font-size: 10pt;">&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td></tr><tr valign="top"><td width="21"><font style="font-size: 10pt;">&#160;</font></td><td width="40"><font style="font-size: 10pt;">[  ]</font></td><td nowrap="nowrap"><font style="font-size: 10pt;">&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td></tr><tr valign="top"><td width="21"><font style="font-size: 10pt;">&#160;</font></td><td width="40"><font style="font-size: 10pt;">[  ]</font></td><td nowrap="nowrap"><font style="font-size: 10pt;">&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td></tr><tr valign="top"><td width="21"><font style="font-size: 10pt;">&#160;</font></td><td width="40"><font style="font-size: 10pt;">[  ]</font></td><td nowrap="nowrap"><font style="font-size: 10pt;">&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td></tr></table><p style="font-size: 10pt; margin: 0pt;">&#160;</p><p style="font-size: 10pt; margin: 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &sect;230.405) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934 (17 CFR&#160;&sect;240.12b-2).&#160;Emerging growth company [&#160;&#160;&#160;]</p><p style="font-size: 10pt; margin: 0pt;">&#160;</p><p style="font-size: 10pt; margin: 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&#160;&#160;&#160;]</p><div style="margin-top: 12pt; margin-bottom: 3pt;"><div style="font-size: 1pt; border-top: Black 1.1pt solid; border-bottom: Black 2.5pt solid; width: 100%;"><font style="font-size: 10pt;">&#160;</font></div>&#160;</div><hr style="page-break-after: always;" noshade="noshade"><p><font style="font-size: 10pt;">  <strong>  </strong></font></p><p><font style="font-size: 10pt;"><strong>Item 8.01. Other Events.</strong></font></p><p><font style="font-size: 10pt;">On September 18, 2017, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</font></p><p><font style="font-size: 10pt;"><strong>  </strong></font></p><p><font style="font-size: 10pt;"><strong>Item 9.01. Financial Statements and Exhibits.</strong></font></p><p><font style="font-size: 10pt;">Exhibit 99.1.   Press release dated September 18, 2017</font></p><p><font style="font-size: 10pt;"></font></p><p><font style="font-size: 10pt;"></font></p><hr style="page-break-after: always;" noshade="noshade"><p align="center"><font style="font-size: 10pt;"><strong>SIGNATURE</strong></font></p><p><font style="font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p><table style="width: 100%;" border="0" cellspacing="0" cellpadding="0"><tr valign="top"><td valign="top" width="49%"><font style="font-size: 10pt;">&#160;</font></td><td style="font-size: 12pt;" colspan="2" valign="top"><font style="font-size: 10pt;"><strong>Pain Therapeutics, Inc.</strong></font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;">&#160;</font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;"></font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">Date: September 18, 2017</font></td><td width="2%"><font style="font-size: 10pt;">By:&#160;</font></td><td style="text-decoration: underline;" width="49%"><font style="font-size: 10pt;">/s/ Remi Barbier&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;">Remi Barbier</font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;">Chairman of the Board of Directors,<br>President and Chief Executive Officer</font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;"></font></td></tr></table><p></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252"><meta name="GENERATOR" content="MSHTML 8.00.7601.18094"></head><body bgcolor="#ffffff"><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><strong>NIH Awards $1.8 Million Research Grant to Pain Therapeutics in Support of a Blood-based Diagnostic for Alzheimer&#8217;s Disease</strong></p><p style="text-align: center;"><p>
 <p align="left">AUSTIN, Texas, Sept.  18, 2017  (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a biopharmaceutical company, announced today it has been awarded an approximately $1.8 million research grant from the National Institutes of Health (NIH).&#160; This grant will support innovative technology developed by the Company to diagnose Alzheimer&#8217;s disease with a simple blood test.<br></p>  <p align="justify">&#8220;Finding a way to diagnose disease at an early-stage is vitally important,&#8221; said Remi Barbier, President &amp; CEO of Pain Therapeutics.&#160; &#8220;A blood test may help detect Alzheimer&#8217;s disease before symptoms occur, or rule out other possible causes of memory problems, or might be used as a biomarker to measure the efficacy of drug candidates during clinical trials.&#8221;</p>  <p align="justify">The NIH's <em>National Institute on Aging</em> awarded this research grant to Pain Therapeutics following a competitive, in-depth evaluation of its technology for scientific and technical merit.</p>  <p align="left">The research grant is a technical-milestone based award that will enable Pain Therapeutics to work collaboratively with leaders in the field to develop a blood-based diagnostic for Alzheimer&#8217;s.&#160; The diagnostic technology is related to PTI-125, Pain Therapeutics&#8217; clinical-stage drug candidate for Alzheimer&#8217;s disease, whose underlying science has been published in <em>Journal of Neuroscience</em>, <em>Neurobiology of Aging</em>, <em>Journal of Biological Chemistry</em>, <em>PLOS-One</em> and other peer-reviewed scientific journals.</p>  <p align="justify"><strong><u>About </u></strong><strong><u>Alzheimer's Disease and Diagnostic</u></strong><br>Alzheimer&#8217;s disease is a progressive brain disorder that slowly destroys memory and thinking skills.&#160; Damage to the brain starts a decade or more before problems appear. During this early stage of disease, people seem to be symptom-free, but toxic changes are taking place in the brain.&#160; Eventually, brain damage becomes widespread and affected people are unable to care for themselves.&#160; Currently, Alzheimer&#8217;s cannot be detected until symptoms appear.&#160; Over five million Americans live with Alzheimer&#8217;s, a number that will increase significantly in the coming years.</p>  <p align="justify">Pain Therapeutics owns all worldwide development and commercial rights to PTI-125 and related technology, including diagnostic, without royalty or milestone obligations to any third-parties.</p>  <p align="justify"><strong><u>About </u></strong><strong><u>Pain Therapeutics, Inc.</u></strong><br>Pain Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel drugs.&#160; The FDA has not yet established the safety or efficacy of any of our drug candidates.&#160; For more information, please visit www.paintrials.com.</p>  <p align="justify"><strong><em>Note Regarding Forward-Looking Statements</em></strong><em>: This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act").&#160; Pain Therapeutics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act.&#160; Examples of such statements include, but are not limited to, statements regarding the safety or effectiveness of PTI-125 and the Company&#8217;s plan to develop a blood-based diagnostic for Alzheimer&#8217;s Disease, or to test its specificity. Such statements are based on management's current expectations, but actual results may differ materially due to various factors.&#160; Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the ability to demonstrate the specificity, safety, efficacy or potential health benefits of a blood-based diagnostic.&#160; For further information regarding these and other risks related to our business, investors should consult our filings with the U.S. Securities and Exchange Commission.</em></p>  <p align="justify"><strong>For More Information Contact:<br></strong>Ruth Araya<br>Pain Therapeutics, Inc.<br>IR@paintrials.com<br>(512) 501-2485</p> </p><p></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
